Table 1 Overview of differentially mutated melanoma cell lines tested.

M257

Wild type

3

CDKN2A R80

12.2 μM

16.4 mM

M202

NRAS^Q61L

2

EGFR amplification, CDKN2A ^-/-

> 20 μM

25.3 mM

M207

NRAS^Q61L

2

MITF amplification, PTEN ^-/+

> 20 μM

25.2 mM

M244

NRAS^Q61L

NT

NT

19.9 μM

22.7 mM

M296

NRAS^Q61L

NT

NT

19.4 μM

9.0 mM

SKMEL173

NRAS^Q61K

NT

NT

> 20 μM

36.5 mM

WM1366

NRAS^Q61L

NT

NT

> 20 μM

8.6 mM

SBCL2

NRAS^Q61L

NT

NT

> 20 μM

2.9 mM

M229

BRAF^V600E homozygous

4

MITF amplification, AKT1 amplification

PTEN ^-/+

0.3 μM

13.0 mM

M233

BRAF^V600E heterozygous

3

AKT1 amplification, CCND1 amplification

EGFR amplification, CDKN2A ^-/-, PTEN ^-/-

> 20 μM

20.2 mM

M238

BRAF^V600E heterozygous

2

CDKN2A ^-/-, PTEN ^-/+

0.1 μM

12.5 mM

M238-AR5

BRAF^V600E heterozygous

2

CDKN2A ^-/-, PTEN ^-/+, PDGFR1b over-expression

> 20 μM

13.1 mM

M249

BRAF^V600E heterozygous

3

MITF amplification, AKT2 amplification, PTEN ^-/-

0.1 μM

9.2 mM

M249-AR4

BRAF^V600E heterozygous

NRAS^Q61K

3

MITF amplification, AKT2 amplification, PTEN ^-/-

> 20 μM

17.9 mM

M255

BRAF^V600E heterozygous

2

AKT2 amplification, CCND1 amplification

EGFR amplification, CDKN2A ^-/-

8.8 μM

17.3 mM

M262

BRAF^V600E homozygous

2

AKT1 E17K, AKT1 amplification

EGFR amplification, CDKN2A ^-/-

0.2 μM

20.5 mM

M263

BRAF^V600E heterozygous

2

CDKN2A ^-/+

19.9 μM

19.6 mM

M308

BRAF^V600E heterozygous

3

MITF amplification

AKT2 amplification, EGFR amplification

CDKN2A-/+

17.3 μM

6.0 mM

SKMEL28

BRAF^V600E homozygous

2

EGFR P753S, MITF amplification

CCND1 amplification, CDKN2A -/+,

PTEN -/+

1.5 μM

29.7 mM